Peregrine Pharmaceuticals announced updated preliminary data from its Phase 2 trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with advanced breast cancer. Nine of the 14 patients achieved an objective tumor response after a maximum of six treatment cycles according to RECIST criteria. The primary objective of this multi-center, open label study is to assess the overall response rate. Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters.
Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS). PS is exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body’s immune system to destroy the tumor and the tumor blood vessels.
For more information call (714) 508-6000 or visit www.peregrineinc.com.